AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33098169 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobaplatin (LBP) with paclitaxel (PTX)
Number of subjects: 120
Study 33098169 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (CBP) with paclitaxel (PTX)
Number of subjects: 120
Study 32570811 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-enriched protein supplement (leucine 3 g, protein mixture 17 g, vitamin D 800 IU, calcium 300 mg, fat 1.1 g, carbohydrate 2.5 g)
Number of subjects: 120
Study 32570811 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate supplement
Number of subjects: 120
Study 32190975 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative care program including condition education, group exercise, and dietary intervention
Number of subjects: 96
Study 35243875 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1112
Study 35243875 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 1112
Study 35243875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1112
Study 33961817 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mg/kg)
Number of subjects: 81
Study 33961817 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 32705925 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (combined with LipiSperse)
Number of subjects: 28
Study 32705925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 36173236 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas (BP) with insulin aspart or insulin lispro (N=107)
Number of subjects: 161
Study 36173236 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SC) control group (N=54)
Number of subjects: 161
Study 35754023 — intervention group
Group type: EXPERIMENTAL
Intervention: TKM-based health promotion program
Number of subjects: 309
Study 35754023 — intervention group
Group type: COMPARATOR
Intervention: Basic services of CCCs
Number of subjects: 309
Study 32014812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab with paclitaxel
Number of subjects: 637
Study 32014812 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 637
Study 32014812 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline biomarkers (CRP, HGF, ICAM-3, IL-8, SAA, VCAM-1)
Number of subjects: 637
Study 32014812 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF-D and PlGF
Number of subjects: 637
Study 32014812 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2
Number of subjects: 637
Study 32014812 — intervention group
Group type: EXPERIMENTAL
Intervention: Other markers
Number of subjects: 637
Study 32014812 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker predictive analysis
Number of subjects: 637
Study 36143882 — intervention group
Group type: EXPERIMENTAL
Intervention: in motion Nd:YAG laser
Number of subjects: 40
Study 36143882 — intervention group
Group type: COMPARATOR
Intervention: traditional Nd:YAG laser
Number of subjects: 40
Study 34847963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 84
Study 32812039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and daclatasvir plus standard care
Number of subjects: 66
Study 32812039 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 66
Study 36229120 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 80
Study 34343296 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin followed by glipizide and then insulin glargine on failure to achieve HbA1c < 6.5%
Number of subjects: 261
Study 34343296 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial triple therapy with metformin/pioglitazone/exenatide
Number of subjects: 261
Study 33778929 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab 105 mg by Autoinjector (AI)
Number of subjects: 180
Study 33778929 — intervention group
Group type: COMPARATOR
Intervention: Etrolizumab 105 mg by Prefilled Syringe with Needle Safety Device (PFS‐NSD)
Number of subjects: 180
Study 32630752 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone accelerometer and gyroscope data analysis using the modified movelet method
Number of subjects: 4
Study 34662553 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gauge cannulas (group 1)
Number of subjects: 33
Study 34662553 — intervention group
Group type: COMPARATOR
Intervention: 18-gauge cannulas (group 2)
Number of subjects: 33
Study 34974502 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of l-Citrulline (CIT)
Number of subjects: 15
Study 34974502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study 35973515 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscapularis tenotomy
Number of subjects: 100
Study 35973515 — intervention group
Group type: COMPARATOR
Intervention: Subscapularis peel
Number of subjects: 100
Study 32430370 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher burnout scores (25%)
Number of subjects: 506
Study 32430370 — intervention group
Group type: COMPARATOR
Intervention: Lower burnout scores
Number of subjects: 506
Study 36079823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritive intervention (meal rich in protein and carbohydrates) after strength training
Number of subjects: 0
Study 36079823 — intervention group
Group type: COMPARATOR
Intervention: Control training (without nutritive intervention)
Number of subjects: 0
Study 36213951 — intervention group
Group type: EXPERIMENTAL
Intervention: Posts before the pandemic featuring at least one food item
Number of subjects: 304
Study 36213951 — intervention group
Group type: COMPARATOR
Intervention: Posts during the pandemic featuring at least one food item
Number of subjects: 304
Study 36213951 — intervention group
Group type: EXPERIMENTAL
Intervention: Posts before the pandemic featuring ultra-processed foods
Number of subjects: 304
Study 36213951 — intervention group
Group type: COMPARATOR
Intervention: Posts during the pandemic featuring ultra-processed foods
Number of subjects: 304
Study 36213951 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketing strategies used before the pandemic
Number of subjects: 304
Study 36213951 — intervention group
Group type: COMPARATOR
Intervention: Marketing strategies used during the pandemic
Number of subjects: 304
Study 36213951 — intervention group
Group type: COMPARATOR
Intervention: Most frequent COVID-19 marketing strategies during the pandemic
Number of subjects: 304
Study 32556749 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 20
Study 32228789 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling and lipid-based nutrient supplementation (LNS)
Number of subjects: 6960
Study 32228789 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined WSHN (water, sanitation, handwashing, and nutrition)
Number of subjects: 6960
Study 32228789 — intervention group
Group type: COMPARATOR
Intervention: Water, sanitation, and handwashing interventions with behavior change messaging
Number of subjects: 6960
Study 33904647 — intervention group
Group type: EXPERIMENTAL
Intervention: Innocor (high airflow resistance)
Number of subjects: 16
Study 33904647 — intervention group
Group type: COMPARATOR
Intervention: Oxycon Pro (low airflow resistance)
Number of subjects: 16
Study 32332608 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-lift position
Number of subjects: 124
Study 32332608 — intervention group
Group type: COMPARATOR
Intervention: Neutral-head position
Number of subjects: 124
Study 33301383 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented group (n=9) ingested 30g of CHO during exercise and 40g of CHO immediately after each training session.
Number of subjects: 18
Study 33301383 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented group (n=9) consumed a non-caloric placebo during exercise.
Number of subjects: 18
Study 35894877 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed endurance training (SET)
Number of subjects: 17
Study 35894877 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 17
Study 33582575 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid receptor antagonist naltrexone (NAL)
Number of subjects: 63
Study 33582575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 63
Study 33582575 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (RUN)
Number of subjects: 63
Study 33582575 — intervention group
Group type: COMPARATOR
Intervention: Walking (WALK)
Number of subjects: 63
Study 32821284 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AER)
Number of subjects: 20
Study 32821284 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RES)
Number of subjects: 20
Study 32821284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Exercise (COM)
Number of subjects: 20
Study 32821284 — intervention group
Group type: COMPARATOR
Intervention: Control Session
Number of subjects: 20
Study 34381173 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment
Number of subjects: 145
Study 34381173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 33352487 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 474
Study 33352487 — intervention group
Group type: COMPARATOR
Intervention: Sublingual buprenorphine-naloxone (BUP-NX)
Number of subjects: 474
Study 34473938 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tricuspid annular plane systolic excursion (TAPSE)
Number of subjects: 55
Study 34473938 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased vector magnitude counts
Number of subjects: 55
Study 34473938 — intervention group
Group type: EXPERIMENTAL
Intervention: Most active phenotype
Number of subjects: 55
Study 33693835 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (280 g whole blueberries and 12 g soluble fiber per day)
Number of subjects: 34
Study 33693835 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care (control)
Number of subjects: 34
Study 33693835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 33012729 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous haemoperfusion (CHP)
Number of subjects: 82
Study 33012729 — intervention group
Group type: COMPARATOR
Intervention: Routine haemoperfusion (HP)
Number of subjects: 82
Study 36051241 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 0
Study 36051241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35077507 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week caregiver-mediated exercises intervention (N = 63; 31 Australian and 32 Dutch)
Number of subjects: 129
Study 35077507 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 66; 32 Australian and 34 Dutch)
Number of subjects: 129
Study 33007286 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 33007286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35596691 — intervention group
Group type: EXPERIMENTAL
Intervention: Batched stepped wedge design
Number of subjects: 0
Study 35596691 — intervention group
Group type: COMPARATOR
Intervention: Standard stepped wedge design
Number of subjects: 0
Study 33494380 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival injection of BTX‐A (3 units); n = 15, 25 eyes
Number of subjects: 31
Study 33494380 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous injection of BTX‐A (3 units); n = 16, 28 eyes
Number of subjects: 31
Study 32955964 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbarium mixture (G. ulmifolia/T. stans) 400 mg before each meal for 90 days
Number of subjects: 40
Study 32955964 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 40
Study 33066862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nardostachys jatamansi (3 g total, 1 capsule 3 times a day for 4 weeks)
Number of subjects: 40
Study 33066862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 36299870 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topical airway anesthesia induction strategy (aerosol inhalation airway anesthesia, subglottic airway anesthesia, and low-dose intravenous anesthetics)
Number of subjects: 0
Study 36299870 — intervention group
Group type: COMPARATOR
Intervention: Conventional induction group (high-dose intravenous anesthetics)
Number of subjects: 0
Study 33388491 — intervention group
Group type: EXPERIMENTAL
Intervention: EVE (leuprorelin + LET + EVE)
Number of subjects: 137
Study 33388491 — intervention group
Group type: COMPARATOR
Intervention: LET (leuprorelin + LET)
Number of subjects: 137
Study 35963531 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facing Jumpstart (Trial 1)
Number of subjects: 2600
Study 35963531 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-directional Jumpstart (Trial 2)
Number of subjects: 2600
Study 35963531 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Trial 1)
Number of subjects: 2600
Study 35963531 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Trial 2)
Number of subjects: 2600
Study 35963531 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facing Jumpstart (Trial 2)
Number of subjects: 2600
Study 34283740 — intervention group
Group type: EXPERIMENTAL
Intervention: Worked Example followed by Problem-Solving (WE-PS)
Number of subjects: 79
Study 34283740 — intervention group
Group type: COMPARATOR
Intervention: Worked Example followed by Worked Example (WE-WE)
Number of subjects: 79
Study 32393559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hypertonic dextrose prolotherapy (DPT)
Number of subjects: 76
Study 32393559 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) injection
Number of subjects: 76
Study 36329428 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + Artz (2.5 ml, 10 mg/ml HA followed by 3 ml PRP)
Number of subjects: 99
Study 36329428 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + HYAJOINT Plus (3 ml, 20 mg/ml cross‐linked HA followed by 3 ml PRP)
Number of subjects: 99
Study 36329428 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 99
Study 35153177 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 120
Study 35153177 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin + IV saline hydration
Number of subjects: 120
Study 32250562 — intervention group
Group type: COMPARATOR
Intervention: Fixed multibrackets appliance (MB)
Number of subjects: 90
Study 32250562 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable clear aligners (CA)
Number of subjects: 90
Study 32250562 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable positioner (RP)
Number of subjects: 90
Study 37616308 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 56
Study 37616308 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 56
Study 34629067 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% calorie-restricted and ketogenic diet combined with aerobic exercise during intravenous chemotherapy
Number of subjects: 50
Study 34629067 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 32769919 — intervention group
Group type: EXPERIMENTAL
Intervention: LED photobiomodulation therapy 3 times a week for 2 weeks
Number of subjects: 148
Study 32769919 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy 3 times a week for 2 weeks
Number of subjects: 148
Study 35283313 — intervention group
Group type: EXPERIMENTAL
Intervention: BTN162b2
Number of subjects: 6544
Study 35283313 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA‐1273
Number of subjects: 6544
Study 35283313 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 followed by an mRNA vaccine
Number of subjects: 6544
Study 35283313 — intervention group
Group type: EXPERIMENTAL
Intervention: Spike‐ACE2‐receptor‐blocking antibodies
Number of subjects: 6544
Study 35283313 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 6544
Study 35549365 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational Savoring (RS)
Number of subjects: 164
Study 35549365 — intervention group
Group type: COMPARATOR
Intervention: Personal Savoring (PS)
Number of subjects: 164
Study 32924226 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional impressions
Number of subjects: 15
Study 32924226 — intervention group
Group type: COMPARATOR
Intervention: IOS groups (CS3600, i500, EZIS PO)
Number of subjects: 15
Study 32756845 — intervention group
Group type: EXPERIMENTAL
Intervention: MS/2 medium supplemented with 100 mg L‐1 of cysteine, 0.5 mg L‐1 of gibberellic acid (AG3) and 30 g L‐1 of sucrose
Number of subjects: 60
Study 34812713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 108
Study 34812713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (fluoxetine)
Number of subjects: 108
Study 34812713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) and/or pharmacological treatment
Number of subjects: 108
Study 34812713 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline impulsivity
Number of subjects: 108
Study 33401168 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate LSTM approach
Number of subjects: 400000000
Study 33401168 — intervention group
Group type: EXPERIMENTAL
Intervention: Recursive multi-step LSTM algorithm
Number of subjects: 400000000
Study 33401168 — intervention group
Group type: COMPARATOR
Intervention: Simple frequency monitoring approach
Number of subjects: 400000000
Study 33139781 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anti-Toxoplasma gondii antibodies in MS patients
Number of subjects: 129
Study 33139781 — intervention group
Group type: COMPARATOR
Intervention: Presence of anti-Toxoplasma gondii antibodies in controls
Number of subjects: 129
Study 33139781 — intervention group
Group type: EXPERIMENTAL
Intervention: History of mononucleosis
Number of subjects: 129
Study 33139781 — intervention group
Group type: EXPERIMENTAL
Intervention: High educational level
Number of subjects: 129
Study 35499744 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (808 nm, 36 J for 360 s) under the tongue
Number of subjects: 0
Study 35499744 — intervention group
Group type: COMPARATOR
Intervention: Photobiomodulation over the radial artery
Number of subjects: 0
Study 35875890 — intervention group
Group type: EXPERIMENTAL
Intervention: Vutrisiran 25 mg every 3 months (Q3M)
Number of subjects: 164
Study 35875890 — intervention group
Group type: COMPARATOR
Intervention: Patisiran 0.3 mg/kg every 3 weeks (Q3W)
Number of subjects: 164
Study 32167389 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 66
Study 32167389 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 66
Study 35703711 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic method for determining working length
Number of subjects: 64
Study 35703711 — intervention group
Group type: COMPARATOR
Intervention: Electronic apex locator for determining working length
Number of subjects: 64
Study 32881639 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge phone calls from a navigator to review the recommended treatment plan and address barriers to engagement on days 3, 7, 14, and 21
Number of subjects: 395
Study 32881639 — intervention group
Group type: COMPARATOR
Intervention: Control group (no post-discharge navigation)
Number of subjects: 395
Study 32282720 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) and electronic moxibustion (EM) + alpha blocker
Number of subjects: 78
Study 32282720 — intervention group
Group type: COMPARATOR
Intervention: Alpha blocker
Number of subjects: 78
Study 33336359 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) infused over 10 minutes
Number of subjects: 27
Study 33336359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosphenytoin (FOS) infused over 10 minutes
Number of subjects: 27
Study 33336359 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic Acid (VPA) infused over 10 minutes
Number of subjects: 27
Study 33336359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosphenytoin (FOS)
Number of subjects: 27
Study 33336359 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic Acid (VPA)
Number of subjects: 27
Study 33317802 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine 0.5 mg h−1 i.v. for 24 h
Number of subjects: 110
Study 33407318 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS messages over 4 weeks to encourage dog walking and play
Number of subjects: 150
Study 33407318 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS messages, dog pedometer, and personalized 'dog steps' diary
Number of subjects: 150
Study 33407318 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 150
Study 32034241 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 50
Study 32034241 — intervention group
Group type: COMPARATOR
Intervention: Platelet-poor plasma (PPP)
Number of subjects: 50
Study 32034241 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP
Number of subjects: 50
Study 35680989 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation‐based Balance Training
Number of subjects: 20
Study 35680989 — intervention group
Group type: COMPARATOR
Intervention: Conventional Intensive Balance Training
Number of subjects: 20
Study 34682455 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent and flexibility training (MFT)
Number of subjects: 142
Study 34682455 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training (MT)
Number of subjects: 142
Study 34682455 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 142
Study 33172627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 647
Study 33172627 — intervention group
Group type: COMPARATOR
Intervention: No exercise program
Number of subjects: 647
Study 36127077 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ICU-VR group
Number of subjects: 300
Study 36127077 — intervention group
Group type: EXPERIMENTAL
Intervention: Late ICU-VR group
Number of subjects: 300
Study 36127077 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 300